ClinicalTrials.gg
RecruitingNCT07532460POTCHICUDUpdated Aug 17, 2026

The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users

An interventional study of 4-aminopyridine (4-AP) and Placebo in Cocaine Use Disorder (CUD) and Cognitive Impairments, sponsored by Boris Quednow. Recruiting at 1 site in Switzerland. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Boris Quednow · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.

Planned enrollment
33rd of 48
40 · median 56
Started
2026
with 2 others
No phase
38 of 61
13 open now
Primary completion
2027-08
later than 10 of 20 live
Registered
59th of 61
by date

Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 33rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 10 of the 20 other live ones, and was the 59th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cognitive Dysfunction with a site in Switzerland, or all of them as a file.
02

Study summary

The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.

Read the detailed description

Chronic cocaine use is associated with impairments in cognitive functions, particularly in working memory, which are thought to contribute to the persistence of addictive behaviors and high relapse rates. Despite the clinical relevance of these cognitive deficits, the underlying neuropharmacological mechanisms remain insufficiently understood.

Preclinical and clinical evidence suggests that potassium channels may play an important role in the regulation of neuronal excitability and cognitive processes, including working memory. However, their contribution to cognitive impairments in individuals with cocaine use disorder has not yet been systematically investigated in humans.

The present study aims to investigate the role of potassium channel modulation in working memory performance in individuals with chronic cocaine use. The study addresses the following key research questions: (1) Does modulation of potassium channels influence working memory performance in individuals with chronic cocaine use? and (2) How are potential effects related to behavioral responses observed during the experimental sessions?

To address these questions, a randomized, controlled, cross-over study will be conducted in participants with a history of chronic cocaine use. Participants will complete a series of neurocognitive tasks assessing working memory and related cognitive domains under controlled experimental conditions. Blood samples will be collected at multiple time points to quantify substance levels and to support the interpretation of behavioral findings. The results of this study may contribute to a better understanding of the neurobiological mechanisms underlying cognitive impairments in cocaine use and inform future research on cognitive dysfunction in substance use disorders.

03

Conditions studied

  • Cocaine Use Disorder (CUD)
  • Cognitive Impairments

Keywords

  • cognitive impairments
  • cocaine use disorder
  • potassium channels
  • working memory
  • 4-aminopyridine
  • fampridine
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current diagnosis of mild, moderate, or severe CoUD according to
  • Minimum cocaine use of 1g/month in the last three months
  • Cocaine as the primary drug of consumption
  • Willingness to abstain from cocaine use at least 72 hours before prior to each study visit
  • Ability to read, understand and provide written
  • To be sufficiently fluent in German
  • Age between 20 and 50 years
  • (BMI) between 19 and 30 kg/m2
  • If applicable: luteal phase of the menstrual cycle
  • For individuals with : use of measures

Exclusion criteria

Exclusion Criteria:

  • Presence or history of severe neurological disorders or head injuries
  • Current diagnosis of an acute or chronic infectious disease
  • If applicable: pregnancy and breastfeeding
  • Lifetime history of any epileptic seizures
  • Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long syndrome
  • laboratory or abnormality that could be a safety issue in the study
  • Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment ( \< 50 ml/min)
  • Known or allergy to 4-aminopyridine
  • Use of potassium channel blockers within the last 3 months
  • Use of psychotropic medication within the last 7 days
  • Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine
  • Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compulsive disorder, or autism spectrum disorder according to
  • Diagnosis of a current episode of depression
  • Current diagnosis of a moderate or severe substance use disorder other than CoUD according than DSM-5
  • Daily cannabis consumption in the past three months
  • (E-Cigarette) Fagerström Test of Nicotine Dependence Score > 5 (strong nicotine dependence)
  • Inability to follow the procedures of the study, e.g., due to language problems
  • Being related to or in any form dependent on the investigator
  • Prior participation (less than two years ago) in a study investigating working memory using the n-back task, the SWM, PAL, RVP, or LNST
  • Participation in another study with drugs within the 30 days preceding and during the present study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sequence AB

    Participants receive fampridine (A) in one experimental session and placebo (B) in the other, in the order A then B.

    Drug: 4-aminopyridine (4-AP) · Drug: Placebo

  • Experimental
    Sequence BA

    Participants receive placebo (B) in one experimental session and fampridine (A) in the other, in the order B then A.

    Drug: 4-aminopyridine (4-AP) · Drug: Placebo

Interventions

  • Drug4-AminopyridineStudies of 4-Aminopyridine4-Aminopyridine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two doses of fampridine administered during one of the two experimental test sessions.

  • DrugPlacebo

    Matching placebo administered during one of the two experimental test sessions.

06

What researchers measure

Primary outcomes

  1. Global Working Memory Performance

    Working memory performance will be assessed using a cognitive test battery covering different domains of working memory, including visuo-spatial (Spatial Working Memory \[SWM\], total errors; Paired Associates Learning \[PAL\], first trial memory score) and verbal-numeric components (Letter Number Sequencing Task \[LNST\], total score; Letter N-Back Task, discrimination index d'). Individual test scores will be standardized (z-transformation) and combined into a global working memory score according to Vonmoos et al (2013).

    Time frame: Baseline and during both experimental sessions

Secondary outcomes

  1. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)

    Neurofilament light chain (NfL), a marker of axonal integrity, and glial fibrillary acidic protein (GFAP), a marker of microglia activation, levels will be analysed to assess potential drug challenge-related brain structural remodelling or to predict the effect of potassium challenge blockade.

    Time frame: Baseline and during both experimental sessions

  2. Subjective ratings of current mood and craving

    Subjective ratings of current mood (affective state, stress) and craving, pre- and post-cue exposure. Current affective state will be assessed using the Positive and Negative Affect Schedule (PANAS; positive affect range: 10-50, negative affect range: 10-50) and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of affective state and stress burden. Current cocaine craving will be assessed using the Cocaine Craving Questionnaire-Brief (CCQ-Brief; total score range: 10-70, with higher scores representing worse outcomes) and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of craving intensity, distinguishing between wanting, needing and having the urge for cocaine.

    Time frame: Baseline and during both experimental sessions

  3. Adverse effects of the study drug

    Potential adverse effects of the study drug will be assessed using the List of Complaints and visual analog scales (VAS; range 0-100, with higher scores indicating greater levels) of perceived effects of the substance, dizziness, drowsiness, nausea and impaired concentration.

    Time frame: During both experimental sessions

  4. Plasma concentration

    Plasma concentration of the study drug

    Time frame: During both experimental sessions

  5. Heart rate variability

    Heart rate variability is recorded during the test sessions to measure the level of stress and to investigate whether the physiological strain of the test is reduced when taking the study drug.

    Time frame: During both experimental sessions

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 15 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 16, 2026
StartActual
May 28, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07532460
Lead sponsor
Boris Quednow
Responsible party
Boris Quednow (Full Professor for Experimental Pharmacopsychology and Psychological Addiction Research, Psychiatric University Hospital, Zurich) — Sponsor-investigator
First posted
Apr 16, 2026
Start date
May 28, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Prof. Dr. rer. nat. Boris B. Quednow, Dr. rer. nat.
Contact
quednow@bli.uzh.ch
+41 58 384 27 77
Laura V Schurek, M. Sc.
Contact
studie-potchicud@bli.uzh.ch
+41 58 384 26 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4-Aminopyridine

Start the discussion